This cohort study characterizes the prevalence of treatment for metastatic non–small cell lung cancer and predictors of its receipt over a time span ranging from when empiric cytotoxic regimens dominated to the recent availability of targeted therapies and immunotherapy.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer | 0 | 10.24 | 01-07-2026 |
| 2 | Temporal Trends in Lung Cancer Cases Diagnosed at Early Stage | 0 | 5.63 | 01-07-2026 |
| 3 | Treatment Delays in Early Age–Onset Colorectal Cancer | 0 | 8.3 | 01-07-2026 |
| 4 | Long-Term Adverse Effects and Complications After Prostate Cancer Treatment | 0 | 9.73 | 01-12-2024 |
| 5 | Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer | 0 | 7.57 | 01-07-2026 |
| 6 | Race, Secondary Treatment, and Survival in Localized Prostate Cancer | 0 | 5.24 | 21-07-2026 |
| 7 | PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression | 0 | 15.58 | 01-07-2026 |
| 8 | Individualized Stereotactic Ablative Radiotherapy for Lung Tumors | 0 | 6.6 | 01-11-2023 |
| 9 | Prognostic Features of Anti-Cancer Drugs Response in Resected/Unresected Primary Non-Small Cell Lung Cancer: A Retrospective Cohort Study | 0 | 7 | 15-07-2026 |